China approves two-dose schedule for GSK's cervical cancer drug
GSK
1,356.00p
10:15 14/11/24
-0.44%
-6.00p
UK pharma giant GSK said China's National Medical Products Administration has approved a two-dose vaccine schedule for its Cervarix treatment in girls aged between 9 to 14 years for the prevention of cervical cancer.
FTSE 100
8,038.63
10:15 14/11/24
n/a
n/a
FTSE 350
4,439.81
10:15 14/11/24
n/a
n/a
FTSE All-Share
4,397.68
10:15 14/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,623.06
10:14 14/11/24
0.08%
16.05
In 2020, there were approximately 110,000 new cases of cervical cancer and 59,000 deaths due to the disease in China, GSK said on Friday.